Annual EBITDA
-$29.51 M
+$12.77 M+30.21%
December 31, 2022
Summary
- As of February 24, 2025, ARDS annual EBITDA is -$29.51 million, with the most recent change of +$12.77 million (+30.21%) on December 31, 2022.
- During the last 3 years, ARDS annual EBITDA has fallen by -$757.00 thousand (-2.63%).
- ARDS annual EBITDA is now -275.35% below its all-time high of -$7.86 million, reached on December 31, 2016.
Performance
ARDS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$869.00 K
-$14.60 M-106.33%
September 30, 2023
Summary
- As of February 24, 2025, ARDS quarterly EBITDA is -$869.00 thousand, with the most recent change of -$14.60 million (-106.33%) on September 30, 2023.
- Over the past year, ARDS quarterly EBITDA has dropped by -$14.60 million (-106.33%).
- ARDS quarterly EBITDA is now -106.33% below its all-time high of $13.73 million, reached on June 30, 2023.
Performance
ARDS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$633.00 K
+$6.42 M+91.02%
September 30, 2023
Summary
- As of February 24, 2025, ARDS TTM EBITDA is -$633.00 thousand, with the most recent change of +$6.42 million (+91.02%) on September 30, 2023.
- Over the past year, ARDS TTM EBITDA has increased by +$6.42 million (+91.02%).
- ARDS TTM EBITDA is now at all-time high.
Performance
ARDS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ARDS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.2% | -106.3% | +91.0% |
| 3 y3 years | -2.6% | +84.8% | +97.1% |
| 5 y5 years | -50.0% | +88.1% | +97.8% |
ARDS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +30.2% | -106.3% | +89.7% | at high | +98.6% |
| 5 y | 5-year | -33.7% | +30.2% | -106.3% | +95.8% | at high | +98.6% |
| alltime | all time | -275.4% | +30.2% | -106.3% | +95.8% | at high | +98.6% |
Aridis Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$869.00 K(-106.3%) | -$633.00 K(-91.0%) |
| Jun 2023 | - | $13.73 M(-322.3%) | -$7.05 M(-75.2%) |
| Mar 2023 | - | -$6.18 M(-15.6%) | -$28.39 M(-3.8%) |
| Dec 2022 | -$29.51 M(-30.2%) | -$7.32 M(+0.5%) | -$29.51 M(-3.5%) |
| Sep 2022 | - | -$7.29 M(-4.2%) | -$30.58 M(-30.9%) |
| Jun 2022 | - | -$7.61 M(+4.3%) | -$44.23 M(+3.4%) |
| Mar 2022 | - | -$7.29 M(-13.1%) | -$42.76 M(+1.1%) |
| Dec 2021 | -$42.28 M(+91.6%) | -$8.39 M(-59.9%) | -$42.28 M(+6.7%) |
| Sep 2021 | - | -$20.93 M(+240.9%) | -$39.62 M(+62.4%) |
| Jun 2021 | - | -$6.14 M(-9.8%) | -$24.39 M(+8.9%) |
| Mar 2021 | - | -$6.81 M(+18.6%) | -$22.40 M(+1.5%) |
| Dec 2020 | -$22.06 M | -$5.74 M(+0.5%) | -$22.06 M(+0.6%) |
| Sep 2020 | - | -$5.71 M(+37.6%) | -$21.93 M(-6.8%) |
| Jun 2020 | - | -$4.15 M(-35.9%) | -$23.53 M(-14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$6.47 M(+15.5%) | -$27.57 M(-4.1%) |
| Dec 2019 | -$28.75 M(+20.6%) | -$5.60 M(-23.3%) | -$28.75 M(+0.4%) |
| Sep 2019 | - | -$7.31 M(-10.7%) | -$28.64 M(+2.7%) |
| Jun 2019 | - | -$8.18 M(+6.9%) | -$27.88 M(+15.3%) |
| Mar 2019 | - | -$7.65 M(+39.3%) | -$24.17 M(+1.4%) |
| Dec 2018 | -$23.83 M(+21.1%) | -$5.49 M(-16.0%) | -$23.83 M(+4.7%) |
| Sep 2018 | - | -$6.54 M(+46.2%) | -$22.75 M(+4.9%) |
| Jun 2018 | - | -$4.48 M(-38.8%) | -$21.68 M(+2.4%) |
| Mar 2018 | - | -$7.32 M(+65.8%) | -$21.18 M(+7.6%) |
| Dec 2017 | -$19.68 M(+150.3%) | -$4.42 M(-19.3%) | -$19.68 M(+28.9%) |
| Sep 2017 | - | -$5.47 M(+37.8%) | -$15.26 M(+55.9%) |
| Jun 2017 | - | -$3.97 M(-31.7%) | -$9.79 M(+68.3%) |
| Mar 2017 | - | -$5.82 M | -$5.82 M |
| Dec 2016 | -$7.86 M | - | - |
FAQ
- What is Aridis Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals annual EBITDA year-on-year change?
- What is Aridis Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Aridis Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Aridis Pharmaceuticals?
- What is Aridis Pharmaceuticals TTM EBITDA year-on-year change?
What is Aridis Pharmaceuticals annual EBITDA?
The current annual EBITDA of ARDS is -$29.51 M
What is the all time high annual EBITDA for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high annual EBITDA is -$7.86 M
What is Aridis Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ARDS annual EBITDA has changed by +$12.77 M (+30.21%)
What is Aridis Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ARDS is -$869.00 K
What is the all time high quarterly EBITDA for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high quarterly EBITDA is $13.73 M
What is Aridis Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ARDS quarterly EBITDA has changed by -$14.60 M (-106.33%)
What is Aridis Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ARDS is -$633.00 K
What is the all time high TTM EBITDA for Aridis Pharmaceuticals?
Aridis Pharmaceuticals all-time high TTM EBITDA is -$633.00 K
What is Aridis Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ARDS TTM EBITDA has changed by +$6.42 M (+91.02%)